Ephrin/Eph Signaling Pathway in Neurodegeneration

Ephrin/Eph Signaling Pathway in Neurodegeneration

Overview

The Eph family of receptor tyrosine kinases and their ephrin ligands are key regulators of cell positioning, synaptic plasticity, and developmental patterning. The Eph/ephrin system mediates bidirectional signaling that controls axonal guidance, synapse formation, and neural circuit assembly. In neurodegenerative diseases, Eph/ephrin signaling is dysregulated and contributes to synaptic dysfunction, impaired regeneration, and neuroinflammation. Understanding this pathway offers therapeutic opportunities for conditions like Alzheimer's disease, Parkinson's disease, and stroke. [@klein2012]

Molecular Mechanisms

Eph Receptor Family

| Receptor | Expression | Primary Ligands | Key Functions |
|----------|-----------|-----------------|---------------|
| EphA1 | Various | Ephrin-A1, A2, A3, A4, A5 | Development, cancer |
| EphA2 | Neurons, epithelium | Ephrin-A1, A2, A3, A4 | Angiogenesis, adhesion |
| EphA3 | Brain | Ephrin-A2, A5 | Synaptic plasticity |
| EphA4 | Neurons, glia | Ephrin-A2, A3, A5, A6 | Synapse, regeneration |
| EphA5 | Neurons | Ephrin-A2, A3, A5 | Development |
| EphA6 | Brain | Ephrin-A2, A3, A5 | Unknown |
| EphA7 | Brain | Ephrin-A2, A3, A4, A5 | Development |
| EphA8 | Brain | Ephrin-A2, A5 | Development |
| EphB1 | Various | Ephrin-B1, B2, B3 | Development |
| EphB2 | Neurons | Ephrin-B1, B2, B3 | Synapse, memory |
| EphB3 | Various | Ephrin-B1, B2, B3 | Development |
| EphB4 | Endothelium | Ephrin-B2 | Angiogenesis |
| EphB6 | Thymus | Ephrin-B1, B2, B3 | Immune function |

Ephrin/Eph Signaling Pathway in Neurodegeneration

Overview

The Eph family of receptor tyrosine kinases and their ephrin ligands are key regulators of cell positioning, synaptic plasticity, and developmental patterning. The Eph/ephrin system mediates bidirectional signaling that controls axonal guidance, synapse formation, and neural circuit assembly. In neurodegenerative diseases, Eph/ephrin signaling is dysregulated and contributes to synaptic dysfunction, impaired regeneration, and neuroinflammation. Understanding this pathway offers therapeutic opportunities for conditions like Alzheimer's disease, Parkinson's disease, and stroke. [@klein2012]

Molecular Mechanisms

Eph Receptor Family

| Receptor | Expression | Primary Ligands | Key Functions |
|----------|-----------|-----------------|---------------|
| EphA1 | Various | Ephrin-A1, A2, A3, A4, A5 | Development, cancer |
| EphA2 | Neurons, epithelium | Ephrin-A1, A2, A3, A4 | Angiogenesis, adhesion |
| EphA3 | Brain | Ephrin-A2, A5 | Synaptic plasticity |
| EphA4 | Neurons, glia | Ephrin-A2, A3, A5, A6 | Synapse, regeneration |
| EphA5 | Neurons | Ephrin-A2, A3, A5 | Development |
| EphA6 | Brain | Ephrin-A2, A3, A5 | Unknown |
| EphA7 | Brain | Ephrin-A2, A3, A4, A5 | Development |
| EphA8 | Brain | Ephrin-A2, A5 | Development |
| EphB1 | Various | Ephrin-B1, B2, B3 | Development |
| EphB2 | Neurons | Ephrin-B1, B2, B3 | Synapse, memory |
| EphB3 | Various | Ephrin-B1, B2, B3 | Development |
| EphB4 | Endothelium | Ephrin-B2 | Angiogenesis |
| EphB6 | Thymus | Ephrin-B1, B2, B3 | Immune function |

Ephrin Ligands

• Ephrin-A ligands (EFNA1-5): GPI-anchored, bind EphA receptors
• Ephrin-B ligands (EFNB1-3): Transmembrane, bind EphB receptors

Bidirectional Signaling

The Eph/ephrin system operates through two complementary signaling directions:

Forward Signaling (receptor on signal-receiving cell):

• Ephrin binding activates Eph receptor tyrosine kinase activity
• Autophosphorylation creates docking sites for SH2 and PTB domain proteins
• Activates PI3K/Akt, MAPK/ERK, and Rho GTPase pathways
• Results in cytoskeletal reorganization, cell adhesion, and migration

• Ephrin transmembrane ligands recruit PDZ domain proteins and Src family kinases
• Bidirectional communication allows for sophisticated tissue patterning

Key Signaling Pathways

| Pathway | Effectors | Functions |
|---------|-----------|-----------|
| PI3K/Akt | PDK1, mTOR | Cell survival, protein synthesis |
| MAPK/ERK | RAF, MEK, ERK | Proliferation, differentiation |
| Rho GTPases | Rac, Rho, Cdc42 | Cytoskeleton dynamics |
| Src | Fyn, Src | Adhesion, migration |

Role in Alzheimer's Disease

Synaptic Dysfunction

EphB2 is critically involved in synaptic function: [@murai2003] [@coon2019]

The downregulation of EphB2 by amyloid-beta oligomers contributes to synaptic failure and cognitive decline in AD. Therapeutic approaches aimed at enhancing EphB2 signaling are being explored as potential treatments for synaptic dysfunction in AD.

Ephrin-A Signaling

• Ephrin-A5 modulates amyloid precursor protein (APP) processing
• EphA4 activation contributes to synaptic loss and dendritic spine simplification
• EphA4 antagonists promote synaptic repair and functional recovery
• Therapeutic targeting of EphA4 being explored in preclinical models

Regeneration and Plasticity

• Impaired Eph/ephrin signaling contributes to regenerative failure after injury
• Blocking EphA4 promotes axon regeneration after CNS injury
• Bidirectional signaling regulates neural circuit assembly during development and adulthood

Role in Parkinson's Disease

Dopaminergic System Development

• EphB receptors regulate development of dopaminergic neurons in the substantia nigra
• Axonal guidance molecules influence substantia nigra connectivity and circuit formation
• Eph/ephrin signaling during development may determine vulnerability of dopaminergic neurons

Synaptic Function

• Dysregulated EphB signaling affects striatal synapse function and plasticity
• Contributes to basal ganglia circuit dysfunction in PD
• Alpha-synuclein pathology may disrupt Eph/ephrin signaling pathways

Role in Stroke and Brain Injury

Ischemic Damage

• EphA/ephrin-A signaling is upregulated after stroke and brain injury
• Mediates post-ischemic inflammation and angiogenesis
• Bidirectional signaling affects both neurons and vasculature
• EphA4 and ephrin-A5 are particularly implicated in post-injury responses

Regeneration

• Manipulating Eph/ephrin signaling can promote or inhibit regeneration
• EphA4 antagonists improve functional recovery after stroke [@chen2019]
• EphB2 agonists may enhance synaptic repair
• Peptide-conjugated extracellular vesicles targeting EphA4 rejuvenate aged myelin [@peng2024]

Role in Amyotrophic Lateral Sclerosis

Motor Neuron Function

• EphB signaling affects motor neuron development and synapse formation at the neuromuscular junction
• Dysregulation contributes to neuromuscular junction disruption in ALS models
• EphA4 expression may influence motor neuron vulnerability

Therapeutic Strategies

Targeting Eph Receptors

| Approach | Target | Status | Clinical Candidates |
|----------|--------|--------|-------------------|
| EphA4 antagonists | EphA4 | Preclinical | sEphA4-Fc, peptide conjugates |
| EphB2 agonists/modulators | EphB2 | Preclinical | EphB2-Fc, EphB2 ligands |
| Soluble Eph receptors | Multiple | Preclinical | sEphA5, sEphB2 |
| Peptide agonists | Multiple | Preclinical | EphA4-targeting peptides |

Challenges

• Complexity: Multiple receptors and ligands with overlapping functions
• Bidirectional signaling: Both forward and reverse signals must be considered
• Cell-type specificity: Achieving cell-type selective targeting in the CNS
• Blood-brain barrier: Delivery of large protein therapeutics to the CNS

Cross-Pathway Interactions

• PI3K/AKT/mTOR: Shared downstream signaling with Eph/ephrin pathways
• Synaptic plasticity: EphB2 interaction with NMDA receptors
• Axonal guidance: Core Eph/ephrin function in neural development
• Neuroinflammation: Eph/ephrin modulation of microglial responses

See Also

• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction)
• [Axonal Transport Defects in Neurodegenerative Diseases](/mechanisms/axonal-transport-defects)
• [PI3K/AKT/mTOR Signaling Pathway in Neurodegeneration](/mechanisms/pi3k-akt-mtor-signaling-pathway-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Recent Research Updates (2024-2026)

• [H et al. 2025: Idebenone Mitigates Traumatic-Brain-Injury-Triggered Gene Expression Changes in the Prefrontal Cortex](https://pubmed.ncbi.nlm.nih.gov/40498000/)
• [H et al. 2025: Idebenone Enhances the Early Microglial Response to Traumatic Brain Injury](https://pubmed.ncbi.nlm.nih.gov/40654680/)
• [S et al. 2024: EphA4 Targeting Peptide-Conjugated Extracellular Vesicles Rejuvenate Aged CNS Myelin](https://pubmed.ncbi.nlm.nih.gov/39288278/)

References